Printer Friendly

Clarification requested.

"THE FDA'S REVIEW OF THE DATA ON OPEN POWER MORCELLATION WAS 'INADEQUATE, IRRESPONSIBLE' AND A 'DISSERVICE TO WOMEN'"

WILLIAM H. PARKER, MD (AUDIO COMMENTARY; NOVEMBER 2014)

In the February issue of OBG Management, you quoted me as saying that the recent FDA analysis of power morcellation was inadequate. Actually, what I said was that the "FDA did an inadequate and irresponsible analysis and it has been a disservice to women." I didn't mince words when I spoke and I am appalled by the FDA's lack of rigor in this important matter.

William H. Parker, MD

Santa Monica, California

* The editors respond

We thank Dr. Parker for expressing his concern to us. Although the full title of Dr. Parker's Web exclusive audio was included online, it was truncated in print due to space and may have not conveyed his full meaning to print readers. Dr. Parker's voice, and how it is portrayed within the journal's pages and online, is very important to us.

ANSWERING YOUR CODING QUESTIONS

A reader recently requested assistance for a specific coding challenge. We've asked our reimbursement specialist, Melanie Witt, RN, CPC, COBGC, MA, to provide her insight.

COPYRIGHT 2015 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Comment & Controversy
Author:Parker, William H.
Publication:OBG Management
Article Type:Letter to the editor
Date:Apr 1, 2015
Words:191
Previous Article:Breast cancer survivors should try glycerin-containing products.
Next Article:What billing code for patients with inconclusive viability?

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters